Literature DB >> 18839019

Casein kinase 2 interacts with and phosphorylates ataxin-3.

Rui-Song Tao1, Er-Kang Fei, Zheng Ying, Hong-Feng Wang, Guang-Hui Wang.   

Abstract

OBJECTIVE: Machado-Joseph disease (MJD)/Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an expansion of polyglutamine tract near the C-terminus of the MJD1 gene product, ataxin-3. The precise mechanism of the MJD/SCA3 pathogenesis remains unclear. A growing body of evidence demonstrates that phosphorylation plays an important role in the pathogenesis of many neurodegenerative diseases. However, few kinases are known to phosphorylate ataxin-3. The present study is to explore whether ataxin-3 is a substrate of casein kinase 2 (CK2).
METHODS: The interaction between ataxin-3 and CK2 was identified by glutathione S-transferase (GST) pull-down assay and co-immunoprecipition assay. The phosphorylation of ataxin-3 by CK2 was measured by in vitro phosphorylation assays. Results (1) Both wild type and expanded ataxin-3 interacted with CK2alpha and CK2beta in vitro. (2) In 293 cells, both wild type and expanded ataxin-3 interacted with CK2beta, but not CK2alpha. (3) CK2 phosphorylated wild type and expanded ataxin-3.
CONCLUSION: Ataxin-3 is a substrate of protein kinase CK2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839019      PMCID: PMC5552532          DOI: 10.1007/s12264-008-0605-5

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  34 in total

Review 1.  Protein kinase CK2 and its role in cellular proliferation, development and pathology.

Authors:  B Guerra; O G Issinger
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

Review 2.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

3.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.

Authors:  M Okochi; J Walter; A Koyama; S Nakajo; M Baba; T Iwatsubo; L Meijer; P J Kahle; C Haass
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

4.  Machado-Joseph disease gene product identified in lymphocytes and brain.

Authors:  G Wang; K Ide; N Nukina; J Goto; Y Ichikawa; K Uchida; T Sakamoto; I Kanazawa
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

Review 5.  Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation.

Authors:  J E Allende; C C Allende
Journal:  FASEB J       Date:  1995-03       Impact factor: 5.191

6.  alpha-Synuclein affects the MAPK pathway and accelerates cell death.

Authors:  A Iwata; M Maruyama; I Kanazawa; N Nukina
Journal:  J Biol Chem       Date:  2001-09-17       Impact factor: 5.157

7.  Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212.

Authors:  Lin Yang; Mei Sun; Xia-meng Sun; George Z Cheng; Santo V Nicosia; Jin Q Cheng
Journal:  J Biol Chem       Date:  2007-02-20       Impact factor: 5.157

8.  Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.

Authors:  K Nishiyama; S Murayama; J Goto; M Watanabe; H Hashida; S Katayama; Y Nomura; S Nakamura; I Kanazawa
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

9.  The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development.

Authors:  David Y Lou; Isabel Dominguez; Paul Toselli; Esther Landesman-Bollag; Conor O'Brien; David C Seldin
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

10.  Structural and functional analysis of ataxin-2 and ataxin-3.

Authors:  Mario Albrecht; Michael Golatta; Ullrich Wüllner; Thomas Lengauer
Journal:  Eur J Biochem       Date:  2004-08
View more
  7 in total

Review 1.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

2.  Trinucleotide repeats: a structural perspective.

Authors:  Bruno Almeida; Sara Fernandes; Isabel A Abreu; Sandra Macedo-Ribeiro
Journal:  Front Neurol       Date:  2013-06-20       Impact factor: 4.003

3.  Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.

Authors:  Mário N Laço; Luisa Cortes; Sue M Travis; Henry L Paulson; A Cristina Rego
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 4.  Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases.

Authors:  Fabio Sambataro; Maria Pennuto
Journal:  Front Mol Neurosci       Date:  2017-03-31       Impact factor: 5.639

Review 5.  A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.

Authors:  Sean L Johnson; Wei-Ling Tsou; Matthew V Prifti; Autumn L Harris; Sokol V Todi
Journal:  Front Mol Neurosci       Date:  2022-09-14       Impact factor: 6.261

6.  Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models.

Authors:  Carlos A Matos; Clévio Nóbrega; Susana R Louros; Bruno Almeida; Elisabete Ferreiro; Jorge Valero; Luís Pereira de Almeida; Sandra Macedo-Ribeiro; Ana Luísa Carvalho
Journal:  J Cell Biol       Date:  2016-02-15       Impact factor: 10.539

Review 7.  Roles of Post-translational Modifications in Spinocerebellar Ataxias.

Authors:  Linlin Wan; Keqin Xu; Zhao Chen; Beisha Tang; Hong Jiang
Journal:  Front Cell Neurosci       Date:  2018-09-19       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.